Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable…
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025 11:45 ET | Source: Vor Biopharma Treatment with telitacicept…
BlueWillow Biologics Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BlueWillow Biologics, Inc.,…
Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa
DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive…
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Investor webcast to be held on Monday November 3, 2025 at 8:00…
Mutuum Finance (MUTM) Progresses Through Roadmap Phase 2 as It Attracts Over 17,600 Participants
Dubai, UAE, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) continues to…
ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase…
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM),…
Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference
October 24, 2025 12:00 ET | Source: Flare Therapeutics Inc. FX-909, the…
